These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 18040236)

  • 1. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.
    Priglinger SG; Wolf AH; Kreutzer TC; Kook D; Hofer A; Strauss RW; Alge CS; Kunze C; Haritoglou C; Kampik A
    Retina; 2007 Oct; 27(8):1004-12. PubMed ID: 18040236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
    Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
    Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ).
    Algvere PV; Von Wendt G; Gudmundsson J; Seregard S; Kvanta A
    Acta Ophthalmol; 2010 Dec; 88(8):836-41. PubMed ID: 19900206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
    Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R
    Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion.
    Kreutzer TC; Alge CS; Wolf AH; Kook D; Burger J; Strauss R; Kunze C; Haritoglou C; Kampik A; Priglinger S
    Br J Ophthalmol; 2008 Mar; 92(3):351-5. PubMed ID: 18211925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
    Rensch F; Jonas JB; Spandau UH
    Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial.
    Prager F; Michels S; Kriechbaum K; Georgopoulos M; Funk M; Geitzenauer W; Polak K; Schmidt-Erfurth U
    Br J Ophthalmol; 2009 Apr; 93(4):452-6. PubMed ID: 19074916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion.
    Pai SA; Shetty R; Vijayan PB; Venkatasubramaniam G; Yadav NK; Shetty BK; Babu RB; Narayana KM
    Am J Ophthalmol; 2007 Apr; 143(4):601-6. PubMed ID: 17306753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of bevacizumab as the primary treatment for retinal vein occlusions.
    Figueroa MS; Contreras I; Noval S; Arruabarrena C
    Br J Ophthalmol; 2010 Aug; 94(8):1052-6. PubMed ID: 20679089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
    Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
    Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.
    Rabena MD; Pieramici DJ; Castellarin AA; Nasir MA; Avery RL
    Retina; 2007; 27(4):419-25. PubMed ID: 17420692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial.
    Zhang H; Liu ZL; Sun P; Gu F
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):615-21. PubMed ID: 21823986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.
    Epstein DL; Algvere PV; von Wendt G; Seregard S; Kvanta A
    Ophthalmology; 2012 Dec; 119(12):2587-91. PubMed ID: 22902212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
    Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
    Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
    Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
    Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion.
    Gregori NZ; Gaitan J; Rosenfeld PJ; Puliafito CA; Feuer W; Flynn HW; Berrocal AM; Al-Attar L; Dubovy S; Smiddy WE; Schwartz SG; Lee WH; Murray TG
    Retina; 2008 Oct; 28(9):1325-37. PubMed ID: 19430392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.